NIH Launches Trial of Rigel Drug for Severe COVID-19 NIH Launches Trial of Rigel Drug for Severe COVID-19
The NIH on Thursday launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe COVID-19.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 19, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

We Need a COVID-19 Vaccine. We Also Need Transparency About Its Development
The authorization of an effective vaccine will mark perhaps the biggest turning point in the battle against coronavirus, but only if enough people are willing to get vaccinated. There have been substantial declines in public willingness to get vaccinated against COVID-19, despite immense, unprecedented public investments in vaccine development. In one survey, barely half of Americans said they would get the vaccine as soon as it was available, numbers that will undermine the benefits of even a highly effective vaccine. It is no mystery why trust in a potential vaccine has plummeted. Operation Warp Speed, the Trump Administ...
Source: TIME: Health - September 18, 2020 Category: Consumer Health News Authors: Dr. Ashish K. Jha Tags: Uncategorized COVID-19 Source Type: news

Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Coronavirus Vaccine: Moderna and Pfizer Reveal Secret Blueprints Trials
The companies hope to earn the trust of the public and of scientists who have clamored for details of the studies. (Source: NYT)
Source: NYT - September 18, 2020 Category: American Health Authors: Denise Grady and Katie Thomas Tags: Coronavirus (2019-nCoV) Vaccination and Immunization Clinical Trials Moderna Inc Source Type: news

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys ® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.1 Specifically, the test targets antibodies which are directed against the ...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys ® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.1 Specifically, the test targets antibodies which are directed against the ...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

UM receives largest single research award in its history
(The University of Montana) The National Institutes of Health has awarded the University of Montana a five-year, $33.4 million award for the development and clinical trials of opioid vaccines. It is the largest such award in University history. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2020 Category: International Medicine & Public Health Source Type: news

Immunotherapy improves survival in advanced bladder cancer patients
(Queen Mary University of London) An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2020 Category: International Medicine & Public Health Source Type: news

When Will You Be Able to Get a Coronavirus Vaccine?
Despite the president ’s repeated claims that a vaccine will be available in October, scientists, companies and federal officials all say that most people won’t get one until well into next year. (Source: NYT Health)
Source: NYT Health - September 18, 2020 Category: Consumer Health News Authors: Katie Thomas and Jesse Drucker Tags: Clinical Trials Shortages Vaccination and Immunization Coronavirus (2019-nCoV) United States Politics and Government AstraZeneca PLC Advisory Committee on Immunization Practices Centers for Disease Control and Prevention Food and Drug Admi Source Type: news

Kochi-based company to start phase 2b trials of COVID drug next week
PNB Vesper Life ’s chief executive PN Balaram is upbeat the company’s experimental drug PNB-001 will be effective in treating symptoms of Covid-19. The Kochi-based pharma company is set to begin clinical trials on patients suffering from the disease next week. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 18, 2020 Category: Pharmaceuticals Source Type: news

AI Algorithm on Par With Radiologists as Mammogram Reader AI Algorithm on Par With Radiologists as Mammogram Reader
Because AI has reached such high levels of accuracy in reading mammograms, it is time to test the technology in rigorous, prospective clinical trials, said an expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

There ’s Only Weak Evidence For Vitamin-D As a COVID-19 Preventative—But Scientists Are Trying to Learn More
To protect himself from COVID-19, Dr. Anthony Fauci has long said he’s skipping hugs and handshakes, wearing a mask, and staying off of planes. Last week, he acknowledged adding another step to protect his health: taking supplements of vitamin-D. “If you are deficient in Vitamin-D, that does have an impact on your susceptibility to infection,” Fauci, head of the National Institute of Allergy and Infectious Diseases, said in an interview posted on Instagram last week. “So I would not mind recommending—and I do it myself—taking vitamin-D supplements.” However, while spurious claims t...
Source: TIME: Health - September 17, 2020 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Source Type: news

Moderna Shares the Blueprint for Its Coronavirus Vaccine Trial
The company hopes to earn the trust of the public and of scientists who have clamored for details of its study. (Source: NYT)
Source: NYT - September 17, 2020 Category: American Health Authors: Denise Grady and Katie Thomas Tags: Coronavirus (2019-nCoV) Vaccination and Immunization Clinical Trials Moderna Inc Source Type: news

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support. Objective To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. Design, Setting, and Participants Prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were con...
Source: Current Awareness Service for Health (CASH) - September 17, 2020 Category: Consumer Health News Source Type: news

Recruitment and retention of older adults in assisted living facilities to a clinical trial using technology for falls prevention: a qualitative case study of barriers and facilitators - Meekes WMA, Ford C, Stanmore EK.
Older adults often have health complexities and higher levels of attrition. Even though they are the main users of healthcare, they are often not included in health research because the health research may not be well designed to accommodate their evolving... (Source: SafetyLit)
Source: SafetyLit - September 17, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Psychological intervention with parents improves treatment results and reduces punishment in enuretic children: a randamized clinical trial - S á CA, Martins de Souza SA, Villela MCBVA, Souzaa VM, de Souza MHF, de Figueiredo AA, de Bessa J, Netto JMB.
This study aims to evaluate the impact of psychological intervention with parents of enuretic children on treatment outcome. MATERIAL AND METHODS: Sixty-six enuretic children were randomized into two groups. All children received urotherapy or... (Source: SafetyLit)
Source: SafetyLit - September 17, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Eli Lilly Claims Experimental Drug Protects Covid-19 Patients
A so-called monoclonal antibody lowered levels of the coronavirus and prevented hospitalizations. The research has not yet been vetted by independent experts. (Source: NYT Health)
Source: NYT Health - September 17, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Antibodies Clinical Trials Eli Lilly and Company National Institutes of Health United States Source Type: news

Alzheimer's Disease Clinical Trial Participation Motivations Alzheimer's Disease Clinical Trial Participation Motivations
What motivates individuals to participate in, and stay involved with, Alzheimer's disease clinical trials?The Gerontologist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 17, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Access to cancer medicines and clinical trials show stark variations across Europe
(European Society for Medical Oncology) Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries, according to results from studies presented at ESMO 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

C-Path launches consortium to support medical product development in sickle cell disease
(Critical Path Institute (C-Path)) C-Path) today announced the launch of the Critical Path for Sickle Cell Disease (CP-SCD) Consortium to support collaboration and regulatory endorsement of new medical product development tools for sickle cell disease. These tools will help to optimize and de-risk clinical trials to increase efficiency in developing and delivering safe, effective treatments for people living with sickle cell disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 17, 2020 Category: International Medicine & Public Health Source Type: news

How this Stanford biotech spinout plans to quickly boost gene therapy
The Peninsula startup snared a $45 million Series A round but plans to start a clinical trial in sickle cell disease as early as the first half of next year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 16, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Companion Drug Might Help Prevent Kidney Complications of Lupus
WEDNESDAY, Sept. 16, 2020 -- Adding a newer drug to standard therapy might help control kidney complications caused by the autoimmune disease lupus, a new clinical trial suggests. The researchers found that adding the drug, called belimumab,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 16, 2020 Category: General Medicine Source Type: news

COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology, PLOS Medicine
Review states large RCTs with appropriate monitoring are required to determine if chloroquine and hydroxychloroquine have preventive or treatment efficacy in COVID-19 and acceptable safety; and their use outside of clinical trials is not justified at this time. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 16, 2020 Category: Consumer Health News Source Type: news

How this Stanford biotech spinout plans to quickly boost gene therapy
The Peninsula startup snared a $45 million Series A round but plans to start a clinical trial in sickle cell disease as early as the first half of next year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Ely Lilly Claims Experimental Drug Protects Covid-19 Patients
A so-called monoclonal antibody lowered blood levels of the coronavirus and prevented hospitalizations. The research has not yet been vetted by independent experts. (Source: NYT Health)
Source: NYT Health - September 16, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Antibodies Clinical Trials Eli Lilly and Company National Institutes of Health United States Source Type: news

After failed clinical trial, aging-focused drug company Unity Bio to cut staff by 30%
Unity Biotechnology Inc., whose clinical trial in osteoarthritis of the knee failed last month in clearing away dead cells thought to play a role in inflammation, will cut 30% of its workforce to focus its remaining cash on eye and brain diseases. One of the first wave of so-called aging drug companies — concentrating on therapies to tackle aging-associated diseases — the South San Francisco company (NASDAQ: UBX) said Tuesday it plans to end the year with about 75 full-time employees. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Parkinson's Drug Levodopa Eyed as Treatment for Severe Macular Degeneration
WEDNESDAY, Sept. 16, 2020 -- A drug long used to treat Parkinson's disease may benefit patients with a severe form of age-related macular degeneration (AMD), a small clinical trial suggests. One of the leading causes of vision loss in older people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 16, 2020 Category: General Medicine Source Type: news

Clinical trial to study psilocybin therapy for depression in cancer patients
(The Reis Group) The first clinical trial to test the safety and feasibility of psilocybin therapy with simultaneous group administration and one-on-one patient support to treat depression in cancer patients was launched today by Maryland Oncology Hematology at the Aquilino Cancer Center at Adventist HealthCare Shady Grove Medical Center. A lead therapist will oversee groups of two to four patients receiving a synthetic form of psilocybin, with constant one-on-one attention from trained therapists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2020 Category: International Medicine & Public Health Source Type: news

Over 30 vaccine candidates supported, 3 in advance trials, 4 in advanced pre-clinical stage: Govt
Union Minister of State for Home Nityanand Rai also told the Rajya Sabha that 13 clinical trials of repurposed drugs have been undertaken to build a portfolio of therapeutic options for COVID-19 patients. (Source: The Economic Times)
Source: The Economic Times - September 16, 2020 Category: Consumer Health News Source Type: news

After failed clinical trial, aging-focused drug company Unity Bio to cut staff by 30%
Unity Biotechnology Inc., whose clinical trial in osteoarthritis of the knee failed last month in clearing away dead cells thought to play a role in inflammation, will cut 30% of its workforce to focus its remaining cash on eye and brain diseases. One of the first wave of so-called aging drug companies — concentrating on therapies to tackle aging-associated diseases — the South San Francisco company (NASDAQ: UBX) said Tuesday it plans to end the year with about 75 full-time employees. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 15, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

After failed clinical trial, aging-focused drug company Unity Bio to cut staff by 30%
Unity Biotechnology Inc., whose clinical trial in osteoarthritis of the knee failed last month in clearing away dead cells thought to play a role in inflammation, will cut 30% of its workforce to focus its remaining cash on eye and brain diseases. One of the first wave of so-called aging drug companies — concentrating on therapies to tackle aging-associated diseases — the South San Francisco company (NASDAQ: UBX) said Tuesday it plans to end the year with about 75 full-time employees. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 15, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Turmeric Capsules Reduce Knee Osteoarthritis Pain Turmeric Capsules Reduce Knee Osteoarthritis Pain
People with knee osteoarthritis who take daily turmeric capsules feel less pain in the knee joint than their peers who don't take this supplement, a clinical trial suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Covid vaccine developer to start clinical trial this month
Oral Covid vaccine hopeful Vaxart Inc. will start enrolling people in its first clinical trial this month against the deadly viral killer. Shares of the South San Francisco company (NASDAQ: VXRT) jumped as much as 60% Monday to $8.47 from Friday's close after Vaxart said the Food and Drug Administration greenlighted its trial plan. Shares settled at $7.78 per share, up 47%. Vaxart's approach stands out against conventional vaccines because it is oral, so it could be distributed more easily and… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 14, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Covid vaccine developer to start clinical trial this month
Oral Covid vaccine hopeful Vaxart Inc. will start enrolling people in its first clinical trial this month against the deadly viral killer. Shares of the South San Francisco company (NASDAQ: VXRT) jumped as much as 60% Monday to $8.47 from Friday's close after Vaxart said the Food and Drug Administration greenlighted its trial plan. Shares settled at $7.78 per share, up 47%. Vaxart's approach stands out against conventional vaccines because it is oral, so it could be distributed more easily and… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 14, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 14, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

First World Evidence Based Healthcare Day to take place on 20 October 2020
Today Cochrane andsix global leaders in evidence-based healthcare, led byJBI, are launching a worldwide initiative to create awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally.The inaugural World Evidence-based Healthcare (EBHC) Day will be held on 20 October 2020 and spotlights the global impact of EBHC on health research, policy, practice and patient outcomes.In 2020, EBHC is a worldwide movement with hundreds of organisations and tens of thousands of individuals working tirelessly towards improving the science and practice of E...
Source: Cochrane News and Events - September 14, 2020 Category: Information Technology Authors: Rachel Klabunde Source Type: news

Is Arthritis Pain Relief as Close as Your Spice Rack?
MONDAY, Sept. 14, 2020 -- It's a must for any good curry, and a new clinical trial suggests that turmeric might ease arthritis pain, too. Researchers found that an extract of the spice turmeric worked better than a placebo in easing pain from knee... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2020 Category: General Medicine Source Type: news

AstraZeneca Resumes UK Trials of COVID-19 Vaccine AstraZeneca Resumes UK Trials of COVID-19 Vaccine
AstraZeneca as resumed British clinical trials of its COVID-19 vaccine after getting the green light from safety watchdogs, the company said on Saturday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2020 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

NIH Launches Clinical Trials of Antithrombotics for COVID-19
MONDAY, Sept. 14, 2020 -- Two of three planned adaptive phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19 have launched, according to an announcement by the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2020 Category: Pharmaceuticals Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Pfizer proposes expanding Covid-19 vaccine trial to include more diversity as race for a vaccine continues
The race for a coronavirus vaccine shows no signs of slowing as more companies move their vaccine candidates through clinical trials, growing closer to determining which will be considered safe and effective. (Source: CNN.com - Health)
Source: CNN.com - Health - September 14, 2020 Category: Consumer Health News Source Type: news

Vaccine Makers Keep Safety Details Quiet, Alarming Scientists
Researchers say drug companies need to be more open about how vaccine trials are run to reassure Americans who are skittish about getting a coronavirus vaccine. (Source: NYT Health)
Source: NYT Health - September 14, 2020 Category: Consumer Health News Authors: Katie Thomas Tags: Clinical Trials Vaccination and Immunization Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Research AstraZeneca PLC Food and Drug Administration Moderna Inc Oxford University Pfizer Inc Krumholz, Harlan M Offit, Paul A Trump, Don Source Type: news

Combining two precision medicines can treat drug-resistant cancers
(Institute of Cancer Research) Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2020 Category: Cancer & Oncology Source Type: news

New study from MD Anderson and BridgeBio's Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer
(University of Texas M. D. Anderson Cancer Center) New preclinical research from MD Anderson and Navire finds a novel drug targeting SHP2 can overcome multiple paths of therapeutic resistance in lung cancer. Navire will launch a clinical trial of SHP2 inhibitors by the end of 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2020 Category: Cancer & Oncology Source Type: news

AstraZeneca Partly Resumes Coronavirus Vaccine Trial After Halting It for Safety
The company said tests of its vaccine would start up again in Britain while remaining suspended in the U.S. and other countries. Pfizer, a competitor, announced an expansion of its trials. (Source: NYT Health)
Source: NYT Health - September 13, 2020 Category: Consumer Health News Authors: Carl Zimmer, Katie Thomas and Benjamin Mueller Tags: your-feed-science Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Research AstraZeneca PLC BioNTech SE Food and Drug Administration Pfizer Inc Source Type: news

Coronavirus: Oxford University resumes vaccine trial; cases in Scotland hit four-month high - live updates
India racks up another 97,570 infections; police disperse demonstrators in Victoria; Brazil deaths climb past 130,000. Follow all the developmentsCovid-19 vaccine gamble: where bets have been placed and why‘World-leadingly bad’: the week Covid resurged in the UKPassengers furious at airlines over voucher policyBob Woodward rejects criticism he sat on Trump ‘deadly’ virus remarks2.41pmBSTDaily coronavirus cases inScotland have hit a four-month high, the latest Scottish government figures show.A total of 221 people have tested positive for the virus in the past 24 hours - the highest daily figure sinc...
Source: Guardian Unlimited Science - September 12, 2020 Category: Science Authors: Damien Gayle , Graham Readfearn and Naaman Zhou (earlier), Aaron Walawalkar(now) Tags: Coronavirus outbreak Infectious diseases Science Medical research Microbiology World news Source Type: news